Three-dimensional printing of patient-specific computed tomography lung phantoms: a reader study.

In modern clinical decision-support algorithms, heterogeneity in image characteristics due to variations in imaging systems and protocols hinders the development of reproducible quantitative measures including for feature extraction pipelines. With the help of a reader study, we investigate the ability to provide consistent ground-truth targets by using patient-specific 3D-printed lung phantoms. PixelPrint was developed for 3D-printing lifelike computed tomography (CT) lung phantoms by directly translating clinical images into printer instructions that control density on a voxel-by-voxel basis. Data sets of three COVID-19 patients served as input for 3D-printing lung phantoms. Five radiologists rated patient and phantom images for imaging characteristics and diagnostic confidence in a blinded reader study. Effect sizes of evaluating phantom as opposed to patient images were assessed using linear mixed models. Finally, PixelPrint's production reproducibility was evaluated. Images of patients and phantoms had little variation in the estimated mean (0.03-0.29, using a 1-5 scale). When comparing phantom images to patient images, effect size analysis revealed that the difference was within one-third of the inter- and intrareader variabilities. High correspondence between the four phantoms created using the same patient images was demonstrated by PixelPrint's production repeatability tests, with greater similarity scores between high-dose acquisitions of the phantoms than between clinical-dose acquisitions of a single phantom. We demonstrated PixelPrint's ability to produce lifelike CT lung phantoms reliably. These phantoms have the potential to provide ground-truth targets for validating the generalizability of inference-based decision-support algorithms between different health centers and imaging protocols and for optimizing examination protocols with realistic patient-based phantoms. Classification: CT lung phantoms, reader study.

PixelPrint: Three-dimensional printing of realistic patient-specific lung phantoms for CT imaging.

Phantoms are essential tools for assessing and verifying performance in computed tomography (CT). Realistic patient-based lung phantoms that accurately represent textures and densities are essential in developing and evaluating novel CT hardware and software. This study introduces PixelPrint, a 3D-printing solution to create patient-specific lung phantoms with accurate contrast and textures. PixelPrint converts patient images directly into printer instructions, where density is modeled as the ratio of filament to voxel volume to emulate local attenuation values. For evaluation of PixelPrint, phantoms based on four COVID-19 pneumonia patients were manufactured and scanned with the original (clinical) CT scanners and protocols. Density and geometrical accuracies between phantom and patient images were evaluated for various anatomical features in the lung, and a radiomic feature comparison was performed for mild, moderate, and severe COVID-19 pneumonia patient-based phantoms. Qualitatively, CT images of the patient-based phantoms closely resemble the original CT images, both in texture and contrast levels, with clearly visible vascular and parenchymal structures. Regions-of-interest (ROIs) comparing attenuation demonstrated differences below 15 HU. Manual size measurements performed by an experienced thoracic radiologist revealed a high degree of geometrical correlation between identical patient and phantom features, with differences smaller than the intrinsic spatial resolution of the images. Radiomic feature analysis revealed high correspondence, with correlations of 0.95-0.99 between patient and phantom images. Our study demonstrates the feasibility of 3D-printed patient-based lung phantoms with accurate geometry, texture, and contrast that will enable protocol optimization, CT research and development advancements, and generation of ground-truth datasets for radiomic evaluations.

Cash transfers as a response to COVID-19: Experimental evidence from Kenya.

We deliver one month's average profit to a randomly selected group of female microenterprise owners in Dandora, Kenya, arriving just in advance of an exponential growth in COVID-19 cases. Relative to a control group, firms recoup about one third of their initial decline in profit, and food expenditures increase. Control profit responds to economic conditions and government announcements during our study period, and treatment effects are largest when control profit is at its lowest. PPE spending and precautionary management practices increase to mitigate the health risks of more intensive firm operation, but only among those who perceive COVID-19 as a major risk.